Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Abstract Background There are many types of therapies for cancer. In these days, immunotherapies, especially immune checkpoint inhibitors, are focused on. Though many types of immune checkpoint inhibitors are there, the difference of effect and its mechanism are unclear. Some reports suggest the res...

Full description

Bibliographic Details
Main Authors: Kazushige Yoshida, Masanori Okamoto, Jun Sasaki, Chika Kuroda, Haruka Ishida, Katsuya Ueda, Hirokazu Ideta, Takayuki Kamanaka, Atsushi Sobajima, Takashi Takizawa, Manabu Tanaka, Kaoru Aoki, Takeshi Uemura, Hiroyuki Kato, Hisao Haniu, Naoto Saito
Format: Article
Language:English
Published: BMC 2020-01-01
Series:BMC Cancer
Subjects:
PD-1
Treg
Osteosarcoma
Anti-PD-1 antibody
Online Access:https://doi.org/10.1186/s12885-019-6499-y

Internet

https://doi.org/10.1186/s12885-019-6499-y

Similar Items